Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is in Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase III clinical trials for topical wound infections and diabetic foot infections. The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Price analytics
Returns
1 day
4.8%
1 week
-1.5%
1 month
-9.7%
3 months
-14.5%
6 months
-30.1%
1 year
-26.1%
3 years
-26.1%
Risk
Volatility (1y ann.)
59.2%
Beta vs ASX 200
0.81
Sharpe (1y)
-0.28
VaR 95% (1-day)
-5.9%
Max drawdown (1y)
-56.0%
Off 1-year high
-53.9%
Technicals
RSI(14)
40
vs 50DMA
-9.5%
vs 200DMA
-32.1%
Trend
Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value81.2
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
100
Price / Sales
0
Growth100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health0.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
0
Debt / Equity
—
Quality (Profitability & Cash Flow)28.4
Return on equity
—
Return on assets
0
Operating margin
82
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum1.5
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
2
Position in 52-week range
5
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).